glp-1 news today More news: in a late-stage study in type 2 diabetes and elevated cardiovascular risk, our new GLP-1 pill showed cardiovascular safety. Read more: https://e.lilly/4myJlm8 Health insurer Cigna will stop
Description
10.1038/npp.2017.150 Neuropsychopharmacology 54 PoesselM.BreuerN.JoshiA.PampelA.VillringerA.HummelT.et al (2020)
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
HR 0.88
Most GLP-1 receptor agonists are injectable, though an oral form (semaglutide, Rybelsus) is also licensed in the UK
The role of novel antidiabetic drugs in diabetic HFpEF Emerging studies indicated that the novel antidiabetic drugs, including SGLT2i, GLP-1 RA and DPP4i, provided the cardiovascular benefits in diabetic HFpEF patients [45,46,47,48,49]
However, like any medication, there may be potential side effects, and its important to discuss the risks and benefits with your healthcare provider
